0000950170-24-097322.txt : 20240814
0000950170-24-097322.hdr.sgml : 20240814
20240814200004
ACCESSION NUMBER: 0000950170-24-097322
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240812
FILED AS OF DATE: 20240814
DATE AS OF CHANGE: 20240814
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Izumi Raquel E.
CENTRAL INDEX KEY: 0001832553
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39244
FILM NUMBER: 241210229
MAIL ADDRESS:
STREET 1: 4500 GREAT AMERICA PKWY
STREET 2: STE. 100 #29
CITY: SANTA CLARA
STATE: CA
ZIP: 95054
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vincerx Pharma, Inc.
CENTRAL INDEX KEY: 0001796129
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 833197402
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 260 SHERIDAN AVENUE
STREET 2: SUITE 400
CITY: PALO ALTO
STATE: CA
ZIP: 94306
BUSINESS PHONE: 650-800-6676
MAIL ADDRESS:
STREET 1: 260 SHERIDAN AVENUE
STREET 2: SUITE 400
CITY: PALO ALTO
STATE: CA
ZIP: 94306
FORMER COMPANY:
FORMER CONFORMED NAME: Vincera Pharma, Inc.
DATE OF NAME CHANGE: 20201223
FORMER COMPANY:
FORMER CONFORMED NAME: LifeSci Acquisition Corp.
DATE OF NAME CHANGE: 20191206
4
1
ownership.xml
4
X0508
4
2024-08-12
false
0001796129
Vincerx Pharma, Inc.
VINC
0001832553
Izumi Raquel E.
260 SHERIDAN AVENUE, SUITE 400
PALO ALTO
CA
94306
true
true
false
false
See Remarks
false
Stock Option (right to buy)
6.26
2024-08-12
4
D
false
76500
D
2032-02-13
Common Stock
76500
0
D
Stock Option (right to buy)
0.55
2024-08-12
4
A
false
76500
A
2032-02-13
Common Stock
76500
76500
D
Stock Option (right to buy)
1.71
2024-08-12
4
D
false
60000
D
2032-08-24
Common Stock
60000
0
D
Stock Option (right to buy)
0.55
2024-08-12
4
A
false
60000
A
2032-08-24
Common Stock
60000
60000
D
Stock Option (right to buy)
0.82
2024-08-12
4
D
false
60000
D
2032-11-14
Common Stock
60000
0
D
Stock Option (right to buy)
0.55
2024-08-12
4
A
false
60000
A
2032-11-14
Common Stock
60000
60000
D
Stock Option (right to buy)
1.17
2024-08-12
4
D
false
90000
D
2033-02-14
Common Stock
90000
0
D
Stock Option (right to buy)
0.55
2024-08-12
4
A
false
90000
A
2033-02-14
Common Stock
90000
90000
D
Stock Option (right to buy)
7.38
2024-08-12
4
D
false
123750
D
2034-03-06
Common Stock
123750
0
D
Stock Option (right to buy)
0.55
2024-08-12
4
A
false
123750
A
2034-03-06
Common Stock
123750
123750
D
Stock Option (right to buy)
7.38
2024-08-12
4
D
false
41250
D
2034-03-06
Common Stock
41250
0
D
Stock Option (right to buy)
0.55
2024-08-12
4
A
false
41250
A
2034-03-06
Common Stock
41250
165000
D
On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the "Repriced Options"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the "Repricing"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors.
Option vests over three years, with 1/3 of the shares vesting on December 23, 2022, and 1/36th of the shares vesting monthly thereafter.
Option vests in twenty-four equal monthly installments starting from August 25, 2022.
Option vests in twenty-four equal monthly installments starting from November 15, 2022.
Option vests in twenty-four equal monthly installments starting from February 15, 2023.
One-third (1/3) vests on March 7, 2025, with the remainder vesting in twenty-four equal monthly installments thereafter.
President and Chief Operations Officer
By: /s/ Alexander A. Seelenberger, attorney-in-fact
2024-08-14